Despite COVID-19, we are operating at full capacity and all project work is operating as usual.

Clinically predictive preclinical efficacy testing services at your disposal

MAY 2, 2014

Pharmatest attended AACR in San Diego

Pharmatest Services Ltd had a very successful meeting in the Annual Meeting of American Association for Cancer Research (AACR) in San Diego, CA, USA on April 5 – 9, 2014. Pharmatest attended the event with a booth and the following scientific presentations:


-          Combination of PI3K inhibitor BAY 1082439 with radium-223 is a promising treatment of cancer with bone metastases (in collaboration with Bayer Pharma AG)

-          Effects of Cabozantinib in the 5TGM1 murine multiple myeloma model (in collaboration with Exelixis Inc.)

-          A new spectrum-selective cathepsin inhibitor, VBY-825, inhibits bone destruction in a syngeneic 5TGM1 multiple myeloma mouse model (in collaboration with Virobay Inc.)


We would like to thank everyone who visited our booth and posters, and everyone else who had interesting discussions with us in the event. We look forward to seeing you all again next year at the AACR in Philadelphia.